Generic Vanrafia Availability
Last updated on May 7, 2025.
Vanrafia is a brand name of atrasentan, approved by the FDA in the following formulation(s):
VANRAFIA (atrasentan hydrochloride - tablet;oral)
-
Manufacturer: NOVARTIS
Approval date: April 2, 2025
Strength(s): EQ 0.75MG BASE [RLD]
Is there a generic version of Vanrafia available?
No. There is currently no therapeutically equivalent version of Vanrafia available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vanrafia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Stabilized pharmaceutical dosage forms comprising atrasentan
Patent 10,016,393
Issued: July 10, 2018
Inventor(s): Huang; Ye et al.
Assignee(s): AbbVie Inc. (North Chicago, IL)The present disclosure relates to: (a) methods of using stabilized pharmaceutical dosage forms comprising atrasentan, or a pharmaceutically acceptable salt thereof, and, optionally, another therapeutic agent to treat type 2 diabetes, microalbuminuria or macroalbuminuria; and (b) methods for the preparation of such pharmaceutical dosage forms.
Patent expiration dates:
- July 7, 2034✓
- July 7, 2034
-
Methods of improving renal function
Patent 11,491,137
Issued: November 8, 2022
Inventor(s): Frohlich; Philip Thomas et al.
Assignee(s): Chinook Therapeutics, Inc. (Seattle, WA)Provided herein are methods of improving kidney function in a subject in need thereof.
Patent expiration dates:
- December 16, 2040✓
- December 16, 2040
-
Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
Patent 11,874,283
Issued: January 16, 2024
Inventor(s): Newman; Gale W. et al.
Assignee(s): Morehouse School of Medicine (Atlanta, GA)The present application relates to methods of treating HIV-associated nephropathy (HIVAN) and/or focal segmental glomerulosclerosis (FSGS) using endothelin-1 (ET-1) antagonists. The application further relates to a composition for the treatment of HIVAN and/or FSGS. A kit for detecting the presence of ET-1 or ET-1-associated biomarker in a biological sample is also disclosed.
Patent expiration dates:
- February 18, 2032✓
- February 18, 2032
-
Methods of improving renal function
Patent 11,998,526
Issued: June 4, 2024
Inventor(s): Frohlich; Philip Thomas et al.
Assignee(s): CHINOOK THERAPEUTICS, INC. (Seattle, WA)Provided herein are methods of improving kidney function in a subject in need thereof.
Patent expiration dates:
- December 16, 2040✓
- December 16, 2040
-
Methods of improving renal function
Patent 12,121,509
Issued: October 22, 2024
Inventor(s): Frohlich; Philip Thomas et al.
Assignee(s): Chinook Therapeutics, Inc. (Seattle, WA)Provided herein are methods of improving kidney function in a subject in need thereof.
Patent expiration dates:
- December 16, 2040✓
- December 16, 2040
-
Therapy for complications of diabetes
Patent 8,623,819
Issued: January 7, 2014
Inventor(s): Roden; Robert L. et al.
Assignee(s): AbbVie Deutschland GmbH & Co. KG (Wiesbaden, DE)A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ET.sub.A) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ET.sub.A receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ET.sub.A receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ET.sub.A receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ET.sub.A receptor antagonist.
Patent expiration dates:
- August 22, 2028✓
- August 22, 2028
-
Stabilized pharmaceutical dosage forms comprising atrasentan
Patent 9,364,458
Issued: June 14, 2016
Inventor(s): Huang; Ye et al.
Assignee(s): AbbVie Inc. (North Chicago, IL)The present disclosure relates to: (a) stabilized pharmaceutical dosage forms comprising atrasenstan, or a pharmaceutically acceptable salt thereof, and, optionally, another therapeutic agent; (b) methods of using such pharmaceutical dosage forms to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising such pharmaceutical dosage forms and, optionally, a second pharmaceutical dosage form comprising another therapeutic agent; (d) methods for the preparation of such pharmaceutical dosage forms; and (e) pharmaceutical dosage forms prepared by such methods.
Patent expiration dates:
- July 7, 2034✓✓
- July 7, 2034
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- April 2, 2030 - NEW CHEMICAL ENTITY
More about Vanrafia (atrasentan)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- Dosage information
- FDA approval history
- Drug class: miscellaneous genitourinary tract agents
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.